SCHEMBL22491397

SCHEMBL22491397

COc1cccc(C(c2ccccc2)C2CN(C(=O)c3ccc4c(c3)NC(=O)CO4)C2)c1

nearest known ligand 0.48

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.48
CYP2C9 P11712 1/20 0.47
NR3C2 P08235 7/20 0.47
TRPV1 Q8NER1 1/20 0.46
THRB P10828 1/20 0.45
RAF1 P04049 1/20 0.45
BRAF P15056 1/20 0.45
GAA P10253 1/20 0.45
POLB P06746 1/20 0.44
MAPT P10636 1/20 0.44
LMNA P02545 2/20 0.44
MAPK1 P28482 1/20 0.44
NR3C1 P04150 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29734336 1.00 ALDH1A1 (0.48) ALDH1A1CYP2C9NR3C2TRPV1THRB
SCHEMBL29734553 0.92 TRPV1 (0.49) ALDH1A1CYP2C9NR3C2TRPV1THRB
SCHEMBL22491414 0.92 TRPV1 (0.49) ALDH1A1CYP2C9NR3C2TRPV1THRB
SCHEMBL29734535 0.92 TRPV1 (0.49) ALDH1A1CYP2C9NR3C2TRPV1THRB
SCHEMBL22491391 0.92 TRPV1 (0.49) ALDH1A1CYP2C9NR3C2TRPV1THRB
SCHEMBL29734488 0.92 TRPV1 (0.49) ALDH1A1CYP2C9NR3C2TRPV1THRB
SCHEMBL22491418 0.92 TRPV1 (0.49) ALDH1A1CYP2C9NR3C2TRPV1THRB
SCHEMBL22491531 0.90 GAA (0.54) ALDH1A1NR3C2GAAMAPTLMNA
SCHEMBL29734345 0.90 GAA (0.54) ALDH1A1NR3C2GAAMAPTLMNA
SCHEMBL22491327 0.89 ALDH1A1 (0.54) ALDH1A1NR3C2GAAPOLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11420961-B2 Heterocyclic compounds HOFFMANN-LA ROCHE INC. (US) 2022-08-23 US claimed
EP-3717477-B1 NEW HETEROCYCLIC COMPOUNDS HOFFMANN LA ROCHE (CH) 2022-07-20 EP claimed
US-20200392125-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2020-12-17 US claimed
EP-3717477-A1 NEW HETEROCYCLIC COMPOUNDS H. Hoffnabb-La Roche Ag (CH) 2020-10-07 EP claimed
US-11420961-B2 Heterocyclic compounds HOFFMANN-LA ROCHE INC. (US) 2022-08-23 US disclosed
EP-3717477-B1 NEW HETEROCYCLIC COMPOUNDS HOFFMANN LA ROCHE (CH) 2022-07-20 EP disclosed
US-20200392125-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2020-12-17 US disclosed
US-20200392125-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2020-12-17 US disclosed
EP-3717477-A1 NEW HETEROCYCLIC COMPOUNDS H. Hoffnabb-La Roche Ag (CH) 2020-10-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11420961-B2 Heterocyclic compounds LPXN, MLX, CCNY ALDH1A1 231/4885CYP2C9 13/4885NR3C2 2484/4885
US-20200392125-A1 HETEROCYCLIC COMPOUNDS LPXN, MLX, CCNY ALDH1A1 231/4885CYP2C9 13/4885NR3C2 2484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.